RegWardenFDA facility compliance records
Facility

SPINEOLOGY INC.

1 recall(s) on record — most severe on record: Class II.

Activity by year

FDA actions on record by year2017: 1 inspections; 2018: 1 inspections; 2022: 1 inspections; 2024: 1 recalls; 2025: 1 inspections120171201820192020202112022202312024120252026
  • Recalls (1)
  • Inspections (4)

Devices registered here (1)

Recalls & enforcement

  • Class IIOngoing2024-09-16
    Possible detachment of the Graft Tube shaft from the Graft Tube funnel head when it is not used as instructed by our surgical technique.

FDA inspections (4)

  • NAI2025-04-17
    No Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted
  • NAI2022-02-15
    No Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted
  • NAI2018-10-12
    No Action Indicated · Bioresearch Monitoring
  • VAI2017-03-31
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted

Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.

Related

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “SPINEOLOGY INC. (FEI 3003179719) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3003179719-spineology-inc/

Not open yet

Alerts for SPINEOLOGY INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.